3 December 2020 - Prophylaxis study
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
et al., The Lancet Healthy Longevity, doi:10.1016/S2666-7568(20)30033-7 (Peer Reviewed)
Retrospective 6,256 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment, statistically significant only for women.
|
risk of death, 7.2% lower, RR 0.93, p = 0.15, treatment 394 of 2,333 (16.9%), control 791 of 3,923 (20.2%), NNT 31, odds ratio converted to relative risk, PSM, all patients.
|
|
risk of death, 24.1% lower, RR 0.76, p = 0.02, treatment 1,129, control 2,173, PSM, women, RR approximated with OR.
|
|
risk of death, 3.5% higher, RR 1.03, p = 0.75, treatment 1,204, control 1,750, PSM, men, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Bramante et al., 12/3/2020, retrospective, database analysis, USA, North America, peer-reviewed, 17 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.